Hepatoma Cell Line That Can Be Infected with Both Hepatitis C and Human Immunodeficiency (HIV-1) Viruses
Posted Jun 20 2010 5:00pm
Description of Invention: It is estimated that 250,000 HIV patients in the U.S. are chronically infected with hepatitis C virus (HCV). Co-infection of HCV and HIV is associated with increased morbidity and mortality relative to mono-infection with either virus. Compared to HCV mono-infected individuals, HCV/HIV co-infected individuals experience rapid progression of liver disease, have higher HCV RNA viral levels, decreased cure rates, and increased toxic reactions to anti-HCV therapy. Understanding how these two viruses interact has been difficult because a cell culture system that supports HCV growth in the laboratory was not available. Recently, a continuous culture system to propagate HCV was discovered, however these cells do not express receptors that allow for infection by HIV. The inventors were able to genetically transform these cells (liver cancer) to express HIV receptors and successfully infect them with both viruses. This modified cell culture system will be useful for studying the interactions between HCV and HIV within the same cell and will serve as a model to understand the pathogenesis of HCV/HIV co-infection.
Use for clinical research to study the pathogenesis of HCV/HIV co-infection.
Use in development of drugs to control both HIV and HCV infections.
The cell line has been fully generated.
Materials will be readily available if so requested.
Research Material -- patent protection is not being pursued for this technology
Matthews GV and Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1000-1008. [ PubMed: 18707597 ]
Licensing Status: Available for licensing.
Portfolios: Infectious Diseases Infectious Diseases - Research Materials
For Additional Information Please Contact: John Stansberry Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5236 Fax: 301-402-0220